S 1734 · 112th Congress 2011โ€“2013, ended

Generating Antibiotic Incentives Now Act of 2011

Latest action · Oct 19, 2011 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedOct 19, 2011
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Generating Antibiotic Incentives Now Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to extend the exclusivity period for a new prescription drug by five years for a drug that the Secretary of Health and Human Services (HHS) determines to be a qualified infectious disease product. Defines "qualified infectious disease product" to mean an antibiotic drug for treating, detecting, preventing, or identifying a qualifying pathogen (certain pathogens that are resistant to antibiotics). Excludes drugs that are: (1) a supplement to a new drug application for which an extension is in effect or has expired; or (2) a subsequent application for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or a modification to the structure of the product that does not result in a change in safety or effectiveness.

Extends such period of exclusivity an additional six months for a sponsor or manufacturer of a qualified infectious disease product that identifies a companion diagnostic test.

Requires the Secretary to give priority review to any drug determined to be a qualified infectious disease product.

Includes qualified infectious disease products as fast track products for which the Secretary shall facilitate development and expedite review.

Directs the Comptroller General to study the need for incentives to encourage the research, development, and marketing of qualified infectious disease biological products.

Requires the Secretary to: (1) review Food and Drug Administration (FDA) guidelines for clinical trials of antibiotic drugs; and (2) revise such guidelines, as appropriate, to reflect developments in scientific and medical information and technology and to ensure clarity regarding the procedures and requirements for approval of an antibiotic drug.

Cosponsors 14

Members who signed on, in the order they did. Signatures ran from Oct 19, 2011 to May 22, 2012; 6 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
R-TNBob CorkerOriginalOct 19, 2011
D-DEChristopher A. CoonsOriginalOct 19, 2011
R-TNLamar AlexanderOriginalOct 19, 2011
D-COMichael F. BennetOriginalOct 19, 2011
R-UTOrrin G. HatchOriginalOct 19, 2011
D-PARobert P. Casey Jr.OriginalOct 19, 2011
R-KSPat RobertsOct 31, 2011
D-MAJohn F. KerryFeb 9, 2012
R-GAJohnny IsaksonFeb 17, 2012
R-GASaxby ChamblissFeb 17, 2012
D-MTJon TesterApr 19, 2012
D-AKMark BegichApr 23, 2012
D-DEThomas R. CarperMay 7, 2012
R-NHKelly AyotteMay 22, 2012

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateHealth, Education, Labor, and Pensions Committee
Referred Oct 19, 2011

Actions 2

Everything that happened, newest first.

  1. Oct 19, 2011Introduced in Senate
  2. Oct 19, 2011Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

CRS reports 2

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 2

Products on other subjects that cite it, usually among other measures.

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
HR 2182Generating Antibiotic Incentives Now Act of 2011Identical billJun 16, 2011

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to provide incentives for the development of qualified infectious disease products.
Short Titles as Introduced
Generating Antibiotic Incentives Now Act of 2011

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Oct 19, 2011Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.